Mr. Brian Pedlar reports

LIFE WITH A CENTRAL LINE [WEBINAR]: KEY CONSIDERATIONS FROM THE PATIENT'S PERSPECTIVE

Covalon Technologies Ltd. has opened registration for a unique, patient-led webinar. The event, scheduled for Wednesday, Sept. 27, 2023, from 1 p.m. to 2 p.m. ET, is designed to provide attendees with a profound look into the patient's world -- living with central vascular access devices.

Guided by the firsthand experiences of Jessika Buehne and Chalice Richert, who are both clinically trained and have navigated the complexities of central vascular access devices, the webinar aims to underscore the necessity of understanding the patient experience, and the importance of compassion in device management and patient care.

"The approach Covalon is taking to listen and amplify the voice of patients speaks volumes," said Ms. Buehne. "It shows we aren't forgotten or aren't just another ID number to a medical product. Knowing hospitals and device companies are listening gives me hope." Ms. Richert added: "Finding the right device for your line and skin can make all the difference. It is encouraging that Covalon is considering how patient needs can differ, and I'm excited for the opportunity share my experience, in hopes that it helps others living with a central line."

Key takeaways from the webinar, titled: "Central vascular access devices: Key considerations from the patient's perspective," include:

• Recognizing the importance of patient-centred device selection;
• Special considerations for long-term IV (intravenous) access;
• Guidance for finding the right device for you, your loved one or patient;
• Best practices for patient-care team engagement;
• Intimate stories, first-hand patient perspectives and real-life experiences;
• A dynamic opportunity to share, learn, discuss and interact.

Webinar details

Title:  Central vascular access devices: Key considerations from the patient's perspective

Speakers:  Ms. Buehne and Ms. Richert

Date:  Wednesday, Sept. 27, 2023, 1 p.m. to 2 p.m. ET

Register:  on-line

Hashtags:  hashtag MARSI, hashtag infectionprevention and hash tag compassionatecare.

Choosing the right medical dressing for a patient can make the difference between pain and comfort, infection and healing, skin injury and skin integrity.

Covalon's soft silicone dressings provide gentle, non-compromising effective care:

• CovaClear IV -- utilizes soft silicone adhesive technology to help protect patients from skin injuries, but does not incorporate anti-microbials, for use with patients who either do not require or cannot tolerate anti-microbials.
• IV Clear -- the world's only dual-anti-microbial vascular access dressing that offers complete transparency at and around the insertion site for easy daily assessment. It also utilizes soft silicone adhesive technology to minimize skin injuries and preserve skin barrier functions, and incorporates safe amounts of anti-microbials, without sacrificing efficacy, to protect against chemical irritation.
• SurgiClear -- the world's only dual-anti-microbial clear postoperative dressing that provides full surgical site visibility, allowing for visual site inspection and thus eliminating the need for early and multiple dressing removals.

For health-care providers that are not able to attend the webinar but are interested in learning more about Covalon's solutions, visit the company's website.

About Covalon Technologies Ltd.

Covalon Technologies is a patient-driven medical device company, built on the relentless pursuit to help the most vulnerable patients have a better chance at healing. Through a strong portfolio of patented technologies and solutions for advanced wound care, infection prevention and medical device coatings, the company offers innovative, gentler and more compassionate options for patients to heal with less infections, less pain and better outcomes. Its solutions are designed for patients and made for care providers. Covalon leverages its patented medical technology platforms and expertise in two ways: (i) by developing products that are sold under Covalon's name; and (ii) by developing and commercializing medical products for other medical companies under development and licence contracts.

We seek Safe Harbor.